Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

The Ambulatory Medical Assistance (AMA) programme during active‐phase treatment in patients with haematological malignancies: A cost‐effectiveness analysis

The Ambulatory Medical Assistance (AMA) programme during active‐phase treatment in patients with... INTRODUCTIONHaematological malignancies (HM) encompass a variety of disease such as lymphoma, lymphoma B, multiple myeloma, Hodgkin's lymphoma (LH), chronic lymphocytic leukaemia (CLL) and other forms of lymphoma. They represent 13 new cases per 100,000 habitants worldwide (Defossez et al., 2019). About two‐thirds of HM are lymphomas (LH and non‐HL).HM, and specifically aggressive lymphomas, are mostly treated with standard cytotoxic chemotherapy. While chemotherapy is associated with improvement in overall survival, it can induce life‐threatening adverse events (AEs) (Habermann et al., 2006; Pfreundschuh et al., 2008). Severe neutropenia is the most critical treatment‐related AE. Frequent but less severe AEs also include constipation, nausea, vomiting, mucositis and neuropathy (15% in the GELA study) (Coiffier et al., 2002).The AEs reduce quality of life and sometimes lead to delays in chemotherapy schedules or even treatment discontinuation. This results in decreases in relative dose intensity (RDI) associated with a reduction in treatment efficacy and of HM survival (Hirakawa et al., 2010).The AEs generally appear during the days following treatment administration when patients are back home and thus are generally managed by phone calls where the patients call the oncology unit and less commonly the primary care provider. Unscheduled patient calls lack reliability and urgency and cause inappropriate use of healthcare http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png European Journal of Cancer Care Wiley

The Ambulatory Medical Assistance (AMA) programme during active‐phase treatment in patients with haematological malignancies: A cost‐effectiveness analysis

Download PDF
9 pages

Loading next page...
 
/lp/wiley/the-ambulatory-medical-assistance-ama-programme-during-active-phase-bKi1OK49gY
Publisher
Wiley
Copyright
© 2022 John Wiley & Sons Ltd
ISSN
0961-5423
eISSN
1365-2354
DOI
10.1111/ecc.13709
Publisher site
See Article on Publisher Site

Abstract

INTRODUCTIONHaematological malignancies (HM) encompass a variety of disease such as lymphoma, lymphoma B, multiple myeloma, Hodgkin's lymphoma (LH), chronic lymphocytic leukaemia (CLL) and other forms of lymphoma. They represent 13 new cases per 100,000 habitants worldwide (Defossez et al., 2019). About two‐thirds of HM are lymphomas (LH and non‐HL).HM, and specifically aggressive lymphomas, are mostly treated with standard cytotoxic chemotherapy. While chemotherapy is associated with improvement in overall survival, it can induce life‐threatening adverse events (AEs) (Habermann et al., 2006; Pfreundschuh et al., 2008). Severe neutropenia is the most critical treatment‐related AE. Frequent but less severe AEs also include constipation, nausea, vomiting, mucositis and neuropathy (15% in the GELA study) (Coiffier et al., 2002).The AEs reduce quality of life and sometimes lead to delays in chemotherapy schedules or even treatment discontinuation. This results in decreases in relative dose intensity (RDI) associated with a reduction in treatment efficacy and of HM survival (Hirakawa et al., 2010).The AEs generally appear during the days following treatment administration when patients are back home and thus are generally managed by phone calls where the patients call the oncology unit and less commonly the primary care provider. Unscheduled patient calls lack reliability and urgency and cause inappropriate use of healthcare

Journal

European Journal of Cancer Care – Wiley

Published: Nov 1, 2022

Keywords: adverse events; chemotherapy; cost‐effectiveness; healthcare quality; monitoring; oncologic nursing

References

  • The efficacy and cost‐effectiveness of patient navigation programs across the cancer continuum: A systematic review
    Bernardo, B. M.; Zhang, X.; Beverly Hery, C. M.; Meadows, R. J.; Paskett, E. D.
  • Cancer care coordinators in stage III colon cancer: A cost‐utility analysis
    Blakely, T.; Collinson, L.; Kvizhinadze, G.; Nair, N.; Foster, R.; Dennett, E.; Sarfati, D.
  • CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large‐B‐cell lymphoma
    Coiffier, B.; Lepage, E.; Brière, J.; Herbrecht, R.; Tilly, H.; Bouabdallah, R.; Morel, P.; Neste, E.; Salles, G.; Gaulard, P.; Reyes, F.; Lederlin, P.; Gisselbrecht, C.
  • Ambulatory Medical Assistance ‐ After Cancer (AMA‐AC): A model for an early trajectory survivorship survey of lymphoma patients treated with anthracycline‐based chemotherapy
    Compaci, G.; Rueter, M.; Lamy, S.; Oberic, L.; Recher, C.; Lapeyre‐Mestre, M.; Laurent, G.; Despas, F.
  • Effectiveness of telephone support during chemotherapy in patients with diffuse large B cell lymphoma: The ambulatory medical assistance (AMA) experience
    Compaci, G.; Ysebaert, L.; Oberic, L.; Derumeaux, H.; Laurent, G.
  • The medical care continuity (MCC) project. A pilot study of video‐assisted home care within the eTEN European Community program. The Italian experience
    Formica, V.; Fossile, E.; Pellegrino, R.; Fatale, M.; Mari, M.; Rabuffetti, M.; Benedetto, F. R.; Visconti, G.; Bollero, E.; Roselli, M.
  • Impacts of a navigation program based on health information technology for patients receiving oral anticancer therapy: The CAPRI randomized controlled trial
    Gervès‐Pinquié, C.; Daumas‐Yatim, F.; Lalloué, B.; Girault, A.; Ferrua, M.; Fourcade, A.; Lemare, F.; Dipalma, M.; Minvielle, E.
  • Economic evaluation of patient navigation programs in colorectal cancer care, a systematic review
    Gerves‐Pinquie, C.; Girault, A.; Phillips, S.; Raskin, S.; Pratt‐Chapman, M.
  • Rituximab‐CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B‐cell lymphoma
    Habermann, T. M.; Weller, E. A.; Morrison, V. A.; Gascoyne, R. D.; Cassileth, P. A.; Cohn, J. B.; Dakhil, S. R.; Woda, B.; Fisher, R. I.; Peterson, B. A.; Horning, S. J.
  • Importance of maintaining the relative dose intensity of CHOP‐like regimens combined with rituximab in patients with diffuse large B‐cell lymphoma
    Hirakawa, T.; Yamaguchi, H.; Yokose, N.; Gomi, S.; Inokuchi, K.; Dan, K.
  • Managing chronic pain in the primary care setting
    Marcus, D. A.
  • Intervention combining nurse navigators (NNs) and a mobile application versus standard of care (SOC) in cancer patients (pts) treated with oral anticancer agents (OAA): Results of CapRI, a single‐center, randomized phase III trial
    Mir, O.; Ferrua, M.; Fourcade, A.; Mathivon, D.; Duflot‐Boukobza, A.; Dumont, S. N.; Baudin, E.; Delaloge, S.; Malka, D.; Albiges, L.; Pautier, P.; Robert, C.; Planchard, D.; Botton, S.; Lemare, F.; Guillet, M.; Puglisi, V.; Abbas, M.; Palma, M.; Minvielle, E.
  • Patient navigators facilitating access to primary care: A scoping review
    Peart, A.; Lewis, V.; Brown, T.; Russell, G.
  • Six versus eight cycles of bi‐weekly CHOP‐14 with or without rituximab in elderly patients with aggressive CD20+ B‐cell lymphomas: A randomised controlled trial (RICOVER‐60)
    Pfreundschuh, M.; Schubert, J.; Ziepert, M.; Schmits, R.; Mohren, M.; Lengfelder, E.; Reiser, M.; Nickenig, C.; Clemens, M.; Peter, N.; Bokemeyer, C.; Eimermacher, H.; Ho, A.; Hoffmann, M.; Mertelsmann, R.; Trümper, L.; Balleisen, L.; Liersch, R.; Metzner, B.
  • Cost‐effectiveness of primary versus secondary prophylaxis with pegfilgrastim in women with early‐stage breast cancer receiving chemotherapy
    Ramsey, S. D.; Liu, Z.; Boer, R.; Sullivan, S. D.; Malin, J.; Doan, Q. V.; Dubois, R. W.; Lyman, G. H.
  • Implementation and maintenance of patient navigation programs linking primary care with community‐based health and social services: A scoping literature review
    Valaitis, R. K.; Carter, N.; Lam, A.; Nicholl, J.; Feather, J.; Cleghorn, L.
  • Establishing common cost measures to evaluate the economic value of patient navigation programs
    Whitley, E.; Valverde, P.; Wells, K.; Williams, L.; Teschner, T.; Shih, Y. C.
  • Oncology nurse phone calls halve the risk of reduced dose intensity of immunochemotherapy: Results of the randomized FORTIS study in chronic lymphocytic leukemia
    Ysebaert, L.; Larcher, M.; Compaci, G.; Oberic, L.; Sahnes, L.; Banos, A.; Araujo, C.; Sommet, A.; Laurent, G.; Despas, F.
  • French innovative leukemia organization CLLg. Overall survival benefit of symptom monitoring in real‐world patients with chronic lymphocytic leukaemia treated with ibrutinib: A FiLO group study
    Ysebaert, L.; Quinquenel, A.; Bijou, F.; Ferrant, E.; Michallet, A. S.